Supercharged immune cells take on Hard-to-Treat blood cancer
NCT ID NCT07509086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of CAR-T cell therapy, boosted with IL-15, in 25 people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, engineered to target cancer cells. The goal is to see if it can shrink tumors and improve response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL-15-armored CAR-T cells (immune cells engineered to target cancer)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat multiple myeloma or plasma cell leukemia.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••